Valuation dashboard for Elutia Inc (ELUT) with P/E 0.60, P/B 2.18, EV/EBITDA -1.13 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction.
Analysis Summary
Elutia Inc reported revenue of $12.3M in the most recent fiscal year, growing at a 5-year CAGR of -22.0%.
Trailing-twelve-month margins: gross margin 57.8%, operating margin -194.0%, net margin 426.9%.
At the current price of $0.81, ELUT trades at a P/E of 0.60 and an ROE of 9.41%. Market capitalisation stands at $36M.
Balance sheet quality for ELUT: current ratio of 2.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 0.60 |
| Price / Book | 2.18 |
| EV / EBITDA | -1.13 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.12 |
| vs Current Price | -84.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ELUT | Elutia Inc | $36M | 0.60 | 2.18 | 9.4% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.81 |
| Market Cap | $36M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 940.81% |
| Return on Invested Capital | -79.27% |
| Return on Assets | 118.69% |
| Gross Margin | 57.82% |
| Operating Margin | -194.03% |
| Net Margin | 426.93% |
Related companies: ANVS · BCAB · CALC · CELU · LTRN · MAIA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of ELUT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks